At a glance
- Originator Novartis
- Class Antineoplastics; Pyridines; Pyrimidines
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Sep 2000 No-Development-Reported for Cancer in European Union (Unknown route)
- 25 Sep 2000 No-Development-Reported for Cancer in USA (Unknown route)
- 25 Nov 1997 Preclinical development for Cancer in USA (Unknown route)